Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 17/20 | 0.41 |
| ▸ | CASP6 | P55212 | 8/20 | 0.38 |
| ▸ | CASP8 | Q14790 | 8/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | CASP9 | P55211 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4551785 | 1.00 | CASP3 (0.41) | CASP3CASP6CASP8CASP7CASP9 | |
| SCHEMBL4553175 | 0.90 | CASP3 (0.48) | CASP3CASP6CASP8CASP7CASP9 | |
| SCHEMBL7642622 | 0.89 | CASP3 (0.34) | CASP3CASP6CASP8CASP7ANPEP | |
| SCHEMBL4553167 | 0.87 | PSMB5 (0.36) | CASP3CASP6CASP8CASP7ANPEP | |
| SCHEMBL4551966 | 0.86 | CASP3 (0.54) | CASP3CASP6CASP8 | |
| SCHEMBL4556890 | 0.86 | CASP3 (0.55) | CASP3CASP6CASP8 | |
| SCHEMBL4556844 | 0.86 | CASP3 (0.55) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL4553453 | 0.86 | CASP1 (0.42) | CASP3CASP6CASP8CASP7ANPEP | |
| SCHEMBL4973269 | 0.86 | CASP3 (0.54) | CASP3CASP6CASP8 | |
| SCHEMBL4564535 | 0.84 | CASP3 (0.40) | CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544951-B2 | Antiinflammatory agents; autoimmune diseases, nervous system degradation | IDUN PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | claimed |
| US-20090214527-A1 | Combination Of Anti-Madcam Antibody And Antifibrotic Caspase Inhibitor To Treat Liver Fibrosis | BURGESS GARY | 2009-08-27 | — | — | US | disclosed |
| EP-1904100-A1 | NEW COMBINATION OF ANTI-MADCAM ANTIBODY AND ANTIFIBROTIC CASPASE INHIBITOR TO TREAT LIVER FIBROSIS | Pfizer Limited (GB) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007007162-A1 | NEW COMBINATION OF ANTI-MADCAM ANTIBODY AND ANTIFIBROTIC CASPASE INHIBITOR TO TREAT LIVER FIBROSIS | PFIZER LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214527-A1 | Combination Of Anti-Madcam Antibody And Antifibrotic Caspase Inhibitor To Treat Liver Fibrosis | CASP5, ADAM17, CASP1 | CASP3 24/4885CASP6 21/4885CASP8 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.